- Details
- Alicia Morgans interviews Omar El-Taji and Ashwin Sachdeva about their JAMA Oncology publication on cardiovascular risks associated with androgen receptor signaling inhibitors (ARSIs) in prostate cancer treatment. Their meta-analysis reveals that ARSIs significantly increase the risk of cardiovascular events across all stages of prostate cancer, with abiraterone and enzalutamide showing the highes...
|
- Details
- Alicia Morgans, MD, MPH joins Charles Ryan, MD highlighting a paper on the risks associated with specific hormonal therapies used to treat breast and prostate cancer that provides an evidence-based approach to prevent and detect adverse cardiovascular outcomes. In this conversation Drs. Morgans and Ryan focus on cardiovascular complications as it associates with prostate cancer. The aim of this co...
|
- Details
- Cardiovascular disease is a leading cause of mortality in patients with prostate cancer, and androgen deprivation therapy (ADT) may worsen cardiovascular risk. Adherence to guideline-recommended assessment and management of cardiovascular risk factors (CVRFs) in patients initiating ADT is not understood. A recently published study that describes CVRF assessment and management in Veterans with pros...
|
- Details
- Cardiovascular complications for men with prostate cancer are predominantly related to the unique situation that these patients fall into when their testosterone decreases due to treatment with androgen deprivation therapy. This is a population that's already vulnerable, an aging male. Joining Alicia Morgans, MD, MPH, is Vivek Narayan, MD, MS to highlight a paper on Cardiovascular Toxicities of Th...
|
- Details
- Prostate cancer and cardiovascular (CV) disease share several risk factors, with the incidence of both rising with increasing age. Systemic prostate cancer therapies may increase CV risk. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a recent paper published in Urologic Oncology: Seminars and Original Investigations titled " Androgen receptor inhibitor treatments...
|
- Details
- Cardiovascular disease and prostate cancer share several risk factors, with the incidence of both rising with increasing age. Systemic prostate cancer therapies may increase CV risk. In this conversation Oliver Sartor, MD, and Alicia Morgans, MD, MPH discuss the possibility of mitigating CV risk by appropriate selection of therapy and counseling patients related to their cardiovascular risk. They...
|
- Details
- Eugene Cone, MD, a urologic oncology fellow at Harvard Medical School, joins Tom Keane, MBBCh, FRCSI, FACS, to discuss the increased risk of cardiac events associated with androgen deprivation therapy, the standard of care for prostate cancer treatment, and the differences in cardiac risk between gonadotropin-releasing antagonists versus agonists. Dr. Cone’s research compared traditional gonadotro...
|
- Details
- Tom Keane discusses a recent publication in European Urology "The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant or Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localized Intermediate-risk Prostate Cancer." Dr. Keane explains that this Phase 2, open-label study demonstrated that oral once-daily relugolix, while not yet FDA a...
|
- Details
- Javid Moslehi joins Alicia Morgans in a conversation on the cardiovascular health of cancer patients. Javid Moslehi's laboratory focuses on mechanistic understanding of cardiovascular toxicities that result from novel “targeted” cancer therapies. In this conversation, they discuss the cardiovascular toxicities associated with androgen deprivation therapy (ADT) and the physiologic mechanisms and ma...
|
